Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Search for prognostic markers of mortality in inpatients receiving palliative chemotherapy.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn many cases, cancer is diagnosed during hospital admission. The rapid development of the cancer can, sometimes, make medical oncologist consider to start chemotherapy treatment (ChT) in an inpatient setting to seek quick symptomatic improvement. However, it remains unclear which patients are going to benefit from this approach. Our purpose is to find prognostic factors that can predict which patients are unlikely to benefit from palliative ChT, helping to avoid unnecessary or harmful treatments and focus care on improving quality of life.
methodsA retrospective, observational analysis was completed of 209 patients with metastatic or locally advanced and unresectable disease that received ChT in inpatient regimen with palliative intent. Traditional clinical parameters (ECOG-PS, Charlson Comorbidity Index-CCI, G8 score) and other novel one (neutrophil-lymphocyte ratio-NLR) were recovered and evaluated at the start of inpatient treatment. 30 and 90 day survival were selected as efficacy outcomes.
results30 and 90 day mortality rates were 22.5% and 39.2%, respectively, for the inpatients starting treatment. ECOG-PS 0-1 was associated with improved 30 and 90 day survivals in comparison with worse ECOG-PS ≥ 2. On the other hand, CCI and G8 score were not related to statistically significant differences in 30 and 90 day survival. NLR < 5 was associated with better 30 and 90 day survival in inpatients starting ChT.
conclusionNLR may be added to ECOG-PS in the choice of inpatients that can benefit from starting treatment during the hospital stay. However, further prospective studies should be carried out to bring light to this matter. The accurate selection of patients is essential to optimize symptoms control and avoid unnecessary treatment toxicity.
Indexed as
Identifiers
41549165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.